Stocks

IBM Stock Tumbles on Long-Awaited CHIPS Act Deal

Guavy AI Editorial Team Published September 16, 2026

Instruments

IBM

IBM stock (no ticker specified) declined by 2.8% in morning trading after its subsidiary Anderon LLC finalized a $1 billion award under the CHIPS and Science Act with the U.S. Department of Commerce. The deal aims to accelerate quantum wafer manufacturing research and development at IBM's 300-millimeter foundry in Albany, New York.

The official announcement seemed to prompt profit-taking among investors, as the deal had been widely anticipated since a letter of intent was disclosed in May 2026.

This news has not provided enough momentum for the stock to recover from its recent stumble. IBM's second-quarter earnings missed estimates on both top and bottom lines, prompting management to trim full-year revenue growth outlook.

The company is still under investigation by multiple securities law firms due to these unresolved overhangs.

IBM Stock Tumbles on Long-Awaited CHIPS Act Deal

Home Depot Shopper's Fake Phone Number Leads to Sunrun Salesperson Surprise

Home Depot Fires Up Savings on Fire Pits and Patio Heaters

Benioff Joins AI Safety Debate, Cautions Tech Giants Over Responsible Development